Study addresses coverage of BPA and GMOs: How ideological interests skew interpretation of contested science

Credit: Kailey Whitman
Credit: Kailey Whitman

When controversies develop around scientific facts or technologies, the potential of science to become a tool in plays of interests and power between different actors is not well recognized. Cordner’s concept of Strategic Science Translation (SST) shows that such actions are enabled by the uncertainty and the complexity of the scientific processes that allow the use of science in support of various, often contradictory interests and goals.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.

In this paper, we… follow how actors “reinterpret” science to serve their interests in two controversies involving animal toxicity studies and their potential relevance for risk assessment in the regulatory context: a two-year rat feeding study in the field of genetically modified (GM) food and an animal study on Bisphenol-A (BPA), a substance widely used in food packaging. Both studies triggered high-profile controversies in the EU.

[I]nterest groups, especially businesses, can use (and potentially distort) science to push policy in desired directions. They can also present their version of scientific facts, while insisting that policy should only be based on what they portray as ‘sound science.’ Although this phrase seems to indicate evidence-based policy, ‘sound science’ was first used by the tobacco industry as a public relations strategy to perpetrate doubt over cigarettes causing cancer.7

To advance their position, by claiming that it is supported by “sound science,” interest groups can also use data published in predatory journals. Published with minimal or without peer-review and quality checks, articles included in these journals are providing evidence of unclear and sometimes little quality while still pretending to [have] scientific robustness.8 The business model of predatory journals has been very successful, with estimates of 15,000 predatory journals in 2020.

This is an excerpt. Read the original post here

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-May-7-2026-12_32_36-PM
Viewpoint: The state of U.S. vaccine policy? Dismal nationally, but some states are stepping up.
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
the magic of mRNA
Viewpoint: Anti-vax fake ‘turbo cancer’ claims threaten cancer treatment breakthroughs
ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claim? The evidence says mostly the opposite
artificial intelligence brain think illustration md
Viewpoint — Digital gods and human extinction: Will we be the first species ever to design our own descendants?
Defense_Secretary_Ash_Carter_tours_the_Microsoft_Cybercrime_Center_in_Seattle_March_3_2016
How criminals are using AI to target social media users and steal their money and confidential data
ChatGPT-Image-May-7-2026-01_23_27-PM-2
Viewpoint: Will AI democratize personalized cancer treatment or fuel medical misinformation?
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
ChatGPT Image May 12, 2026, 01_21_30 PM
How big health brands are funding online medical misinformation 
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.